CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cambridge BioMarketing, an Ashfield company, part of UDG Healthcare plc and the world’s leading rare disease agency, today announced it has been recognized with multiple industry accolades for its cutting-edge campaigns on behalf of rare disease communities around the world.
PM360, the premier information resource for marketing decision makers in the pharmaceutical and medical device sectors, has named Director of Digital Services Annemarie Crivelli to the 2018 PM360 ELITE 100 ‘Digital Crusaders’ list. Now in its fourth year, the PM360 ELITE represents the most influential people in the healthcare industry today. Winners were formally recognized at the annual Elite Awards Party last week in New York City.
“Annemarie is a proven leader in all-things digital, from experiential design to machine learning to data science, and she applies her unparalleled creativity and expertise to lead our digital team and inspire patients around the globe,” said Maureen Franco, Chief Executive Officer, Cambridge BioMarketing.
Cambridge BioMarketing has also been named a winner in several categories by the Hermes Creative Awards:
- ‘Website Overall’ for UnderstandingZSD.com (collaboration with Retrophin Inc.)
- Gold winners:
“We are committed to creating innovative campaigns and tools that reach and unite rare disease patients, caretakers and their medical support network, and we are honored to receive these industry accolades for our recent work,” added Franco.
About Cambridge BioMarketing
Founded in 2001, Cambridge BioMarketing is a U.S.-based communications agency specializing in rare orphan diseases with over 100 employees. Headquartered in Cambridge, MA with offices in Oakland, CA, Cambridge BioMarketing is an industry leader in orphan drug launches, advising pharmaceutical companies with an integrated focus on both traditional healthcare professional (HCP) programs and direct-to-patient work. In partnering with predominantly pharmaceutical and biotech customers, the agency’s goal is to bring physicians, specialists, and patient communities together on behalf of clients to transform human health in the face of devastating, under-appreciated disease states. Cambridge BioMarketing’s primary service offerings include: launch readiness support; digital strategy; market analytics; integrated marketing; patient identification and acquisition; medical affairs support; line extensions and patient retention and adherence programs. For more information, please go to: http://cambridgebmg.com/.
Ashfield, part of UDG Healthcare plc, is a global leader in commercialization services for the healthcare industry. We partner with our clients across Advisory, Healthcare Communications, Commercial, Patient Solutions and Medical Affairs to build creative, scalable and tailored health solutions that are executed flawlessly, to deliver positive outcomes for patients and add value to your business. The company has more than 7,000 employees, operates in 24 countries across Europe, North America, South America and Asia and works with more than 250 businesses, including all of the world’s top 25 pharmaceutical companies. Its mission is to partner with its clients, helping to improve lives by ensuring healthcare professionals and patients get the medicines, knowledge and support they need.
Ashfield provides contract sales teams, customer service reps, medical science liaison officers, remote detailing, nurse educators, medical information, healthcare communications, market access, market research, training, event management, digital, creative, pharmacovigilance, audit and advisory services.
For more information, go to www.ashfieldhealthcare.com.